Results 91 to 100 of about 3,929 (111)

Ivarmacitinib improves patient-reported outcomes across multiple domains in patients with active ankylosing spondylitis: a <i>post hoc</i> analysis of a phase II/III trial. [PDF]

Front Pharmacol
Xu X, Wei H, Liu L, Yang R, Shi Q, Pang D.   +5 more
europepmc   +1 more source

Efficacy of Telerehabilitation for Ankylosing Spondylitis: A Case Report. [PDF]

Cureus
Nakamura K, Tozawa R.
europepmc   +1 more source

Real-World Effectiveness and Safety of Upadacitinib in Tumor Necrosis FactorInhibitor Refractory Axial Spondyloarthritis: 52-Week Outcomes from a Single-Center Cohort. [PDF]

Arch Rheumatol
Bakay U, İzci Duran T.
europepmc   +1 more source

Anti-CD74 IgA as a potential biomarker in axial spondyloarthritis: diagnostic utility and clinical implications. [PDF]

Clin Rheumatol
Ammar GEM, Eldeeb AE, Mourad HA, Tabra SA.   +3 more
europepmc   +1 more source

Prevalence and risk factors of difficult-to-treat axial spondyloarthritis: Real-life evidence from the BioSTaR database. [PDF]

Clin Rheumatol
Bodur H, Ataman Ş, Yurdakul FG, Gürer G, Akgün K, İnceoğlu LA, Sunar İ, Akgül Ö, Sezer İ, Çapkın E, Rezvani A, Yağcı İ, Duruöz MT, Çay HF, Çevik R, Göğüş F, Kamanlı A, Ecesoy H, Güler T, Şahin N, Cengiz G, Melikoğlu MA.   +21 more
europepmc   +1 more source

Correlation Between Serum Procalcitonin and Disease Activity Score in Patients with Ankylosing Spondylitis That Have Hip Involvement. [PDF]

Int J Gen Med
Liang X, Deng B.
europepmc   +1 more source

Use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis receiving biotherapy and associated factors: a prospective cohort study. [PDF]

BMC Rheumatol
Charoui C, El Binoune I, Amine B, El-Kasmi H, Zemrani S, Rostom S, Bahiri R.   +6 more
europepmc   +1 more source

The impact of nurse-led disease management education on outcomes of patients with ankylosing spondylitis: a randomised controlled trial. [PDF]

J Res Nurs
Dağ A, Tulek Z, Seyahi E.
europepmc   +1 more source